Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.47 USD
+0.04 (2.62%)
Updated Apr 23, 2024 01:03 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IDXG 1.47 +0.04(2.62%)
Will IDXG be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IDXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXG
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
Organon (OGN) Q3 Earnings and Revenues Top Estimates
IDXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
UpHealth, Inc. (UPH) Reports Q2 Loss, Lags Revenue Estimates
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates
XpresSpa Group, Inc. (XSPA) Reports Q1 Loss, Tops Revenue Estimates
Other News for IDXG
Interpace Biosciences announces preliminary Q4 revenue of $10.3M
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences reports Q4 EPS 19c vs. (33c) last year
Interpace Biosciences Inc Annual Shareholders Meeting Transcript
Q3 2020 Interpace Biosciences Inc Earnings Call Transcript